Annals of Pharmacotherapy

Papers
(The H4-Index of Annals of Pharmacotherapy is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2− Early Breast Cancer42
The Potential Synergistic Risk of Albuterol and Vasoactives in Acute Lung Injury Trials42
“N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review”33
Daprodustat: A Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease28
Antibody-Mediated Rejection Management Following Lung Transplantation28
Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus25
Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients23
The Impact of Body Weight and Renal Function on the Risk of Bleeding With Direct Oral Anticoagulants in Atrial Fibrillation23
Outcome of Drug-Induced Parkinsonism in the Elderly: A Permanent Nonprogressive Parkinsonian Syndrome May Occur Following Discontinuation of Cinnarizine and Flunarizine23
Choosing Systemic Agents for Psoriasis19
Novel Use of Fostemsavir for 2 Multidrug-Resistant Persons With Human Immunodeficiency Virus18
A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer18
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma16
Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis16
Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice16
Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury16
0.093338966369629